 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...177178179180181182183184185186187...208209» |
- AiTan (rivoceranib) / HLB Bio Group, paclitaxel / Generic mfg.
Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: A phase II, randomized controlled, prospective study (Metro Toronto Convention Centre - Hall E) - Mar 19, 2020 - Abstract #SGO2020SGO_2522;
Apatinib exhibited promising clinical efficacy in cervical cancer patients, resulting in an improved response rate and prolonged progression-free survival compared with the control group, and had manageable side effects. The current study revealed that apatinib combination therapy for adenocarcinoma and bone metastasis were independent prognostic risk factors for disease progression and the risk of mortality.
- fluzoparib (SHR 3162) / Jiangsu Hengrui Medicine
Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and recurrent ovarian cancer (Metro Toronto Convention Centre - Hall E) - Mar 19, 2020 - Abstract #SGO2020SGO_2436;
P1
The current study revealed that apatinib combination therapy for adenocarcinoma and bone metastasis were independent prognostic risk factors for disease progression and the risk of mortality. Fluzoparib had demonstrated promising antitumor activity and an acceptable safety profile in patients with recurrent BRCA1- or BRCA2-mutated ovarian cancer.
- AiTan (rivoceranib) / HLB Bio Group, paclitaxel / Generic mfg.
Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: A phase II, randomized controlled, prospective study (Metro Toronto Convention Centre - Hall E) - Mar 19, 2020 - Abstract #SGO2020SGO_1890;
Apatinib exhibited promising clinical efficacy in cervical cancer patients, resulting in an improved response rate and prolonged progression-free survival compared with the control group, and had manageable side effects. The current study revealed that apatinib combination therapy for adenocarcinoma and bone metastasis were independent prognostic risk factors for disease progression and the risk of mortality.
- fluzoparib (SHR 3162) / Jiangsu Hengrui Medicine
Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and recurrent ovarian cancer (Metro Toronto Convention Centre - Hall E) - Mar 19, 2020 - Abstract #SGO2020SGO_1804;
P1
The current study revealed that apatinib combination therapy for adenocarcinoma and bone metastasis were independent prognostic risk factors for disease progression and the risk of mortality. Fluzoparib had demonstrated promising antitumor activity and an acceptable safety profile in patients with recurrent BRCA1- or BRCA2-mutated ovarian cancer.
- AiTan (rivoceranib) / HLB Bio Group, paclitaxel / Generic mfg.
Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: A phase II, randomized controlled, prospective study (Metro Toronto Convention Centre - Hall E) - Mar 19, 2020 - Abstract #SGO2020SGO_1233;
Apatinib exhibited promising clinical efficacy in cervical cancer patients, resulting in an improved response rate and prolonged progression-free survival compared with the control group, and had manageable side effects. The current study revealed that apatinib combination therapy for adenocarcinoma and bone metastasis were independent prognostic risk factors for disease progression and the risk of mortality.
- fluzoparib (SHR 3162) / Jiangsu Hengrui Medicine
Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and recurrent ovarian cancer (Metro Toronto Convention Centre - Hall E) - Mar 19, 2020 - Abstract #SGO2020SGO_1147;
P1
The current study revealed that apatinib combination therapy for adenocarcinoma and bone metastasis were independent prognostic risk factors for disease progression and the risk of mortality. Fluzoparib had demonstrated promising antitumor activity and an acceptable safety profile in patients with recurrent BRCA1- or BRCA2-mutated ovarian cancer.
- AiTan (rivoceranib) / HLB Bio Group, paclitaxel / Generic mfg.
Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: A phase II, randomized controlled, prospective study (Metro Toronto Convention Centre - Hall E) - Mar 19, 2020 - Abstract #SGO2020SGO_598;
Apatinib exhibited promising clinical efficacy in cervical cancer patients, resulting in an improved response rate and prolonged progression-free survival compared with the control group, and had manageable side effects. The current study revealed that apatinib combination therapy for adenocarcinoma and bone metastasis were independent prognostic risk factors for disease progression and the risk of mortality.
- fluzoparib (SHR 3162) / Jiangsu Hengrui Medicine
Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and recurrent ovarian cancer (Metro Toronto Convention Centre - Hall E) - Mar 19, 2020 - Abstract #SGO2020SGO_512;
P1
The current study revealed that apatinib combination therapy for adenocarcinoma and bone metastasis were independent prognostic risk factors for disease progression and the risk of mortality. Fluzoparib had demonstrated promising antitumor activity and an acceptable safety profile in patients with recurrent BRCA1- or BRCA2-mutated ovarian cancer.
- || AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion date, Trial primary completion date: FZPL-Ib-105: A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC (clinicaltrials.gov) - Mar 19, 2020
P1, N=52, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Fluzoparib had demonstrated promising antitumor activity and an acceptable safety profile in patients with recurrent BRCA1- or BRCA2-mutated ovarian cancer. Trial completion date: Dec 2020 --> Aug 2021 | Trial primary completion date: Dec 2019 --> Apr 2021
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P1 trial: A Drug-drug Interaction Trial of Loperamide Pharmacokinetics Effect on Pyrotinib Maleate (clinicaltrials.gov) - Mar 18, 2020
P1, N=18, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P1 trial: Effect of Low-fat Diet on the Pharmacokinetics of Pyrotinib in Healthy Participants (clinicaltrials.gov) - Mar 18, 2020
P1, N=16, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | plinabulin (BPI 2358) / BeyondSpring
Phase classification: Protective-1: Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 (clinicaltrials.gov) - Mar 17, 2020
P3, N=190, Recruiting, Sponsor: BeyondSpring Pharmaceuticals Inc.
Trial completion date: Dec 2020 --> Aug 2021 | Trial primary completion date: Dec 2019 --> Apr 2021 Phase classification: P2/3 --> P3
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment change, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC (clinicaltrials.gov) - Mar 17, 2020
P2, N=40, Active, not recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase classification: P2/3 --> P3 N=58 --> 40 | Trial primary completion date: Jun 2020 --> Aug 2019
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Enrollment open: A Trial of SHR6390 in Healthy Caucasian Volunteers (clinicaltrials.gov) - Mar 16, 2020
P1, N=36, Recruiting, Sponsor: Atridia Pty Ltd.
N=58 --> 40 | Trial primary completion date: Jun 2020 --> Aug 2019 Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal: Ipsilateral breast metastasis after axillary dissection caused by epithelioid sarcoma: a case report and pathological investigation. (Pubmed Central) - Mar 13, 2020
This rare but interesting case enables breast surgeons and pathologists to accumulate more experience of differential diagnosis of axillary mass for personalized treatment in clinical practice. Meanwhile, ipsilateral breast metastasis of ES we reported in the case urges that clinicians attach greater importance to the tumor metastasis mechanism.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal: Efficacy and Safety of Apatinib in the Treatment of Postoperative Recurrence of Fibrosarcoma. (Pubmed Central) - Mar 13, 2020
Apatinib is a single-drug regimen that can be used in cases of recurrence of fibrosarcoma with high expression of vascular endothelial growth factor receptor-2 (VEGFR-2); its short-term efficacy is excellent, and its side effects are minimal. This drug may be used as part of a regular chemotherapy program.
- | doxorubicin hydrochloride / Generic mfg.
Retrospective data, Journal: Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study. (Pubmed Central) - Mar 13, 2020
This study provides preliminary evidence that the combination of doxorubicin chemotherapy and PD-1 inhibitor for advanced STS is safe and effective. We plan to conduct randomized clinical trials to confirm and characterize the activity of the chemotherapy-immunotherapy combinations in the treatment of sarcomas.
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Quantification of the plasma concentration of apatinib by two-dimensional liquid chromatography (2D-LC). (Pubmed Central) - Mar 12, 2020
We plan to conduct randomized clinical trials to confirm and characterize the activity of the chemotherapy-immunotherapy combinations in the treatment of sarcomas. A simple, convenient, accurate and robust two-dimensional liquid chromatography method was developed and verified, which successfully determined the plasma concentrations of apatinib in gastric cancer patients.
- || ruzinurad (SHR 4640) / Jiangsu Hengrui Pharma
New P1 trial: Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment (clinicaltrials.gov) - Mar 12, 2020
P1, N=24, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||| plinabulin (BPI 2358) / BeyondSpring
Trial completion date, Trial primary completion date: DUBLIN-3: Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC (clinicaltrials.gov) - Mar 11, 2020
P3, N=554, Recruiting, Sponsor: BeyondSpring Pharmaceuticals Inc.
A simple, convenient, accurate and robust two-dimensional liquid chromatography method was developed and verified, which successfully determined the plasma concentrations of apatinib in gastric cancer patients. Trial completion date: Mar 2020 --> Jun 2020 | Trial primary completion date: Feb 2020 --> May 2020
- | AiTan (rivoceranib) / HLB Bio Group, Halaven (eribulin mesylate) / Eisai, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial, PD(L)-1 Biomarker, IO biomarker: Immuno2020-01: A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC (clinicaltrials.gov) - Mar 11, 2020
P2, N=46, Not yet recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- | Avastin (bevacizumab) / Roche, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: HR-BLTN 015: A Phase II Study of Triple-negative Breast Cancer Brain Metastases. (clinicaltrials.gov) - Mar 11, 2020
P2, N=59, Not yet recruiting, Sponsor: Fudan University
- | AiTan (rivoceranib) / HLB Bio Group
Trial primary completion date: HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer (clinicaltrials.gov) - Mar 10, 2020
P=N/A, N=50, Recruiting, Sponsor: Wuhan University
Trial completion date: Mar 2020 --> Jun 2020 | Trial primary completion date: Feb 2020 --> May 2020 Trial primary completion date: Nov 2018 --> Nov 2020
- | Endostar (recombinant human endostatin) / Simcere, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC (clinicaltrials.gov) - Mar 10, 2020
P2, N=52, Recruiting, Sponsor: Beijing Cancer Hospital
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New P1 trial: A Trial of SHR6390 in Healthy Caucasian Volunteers (clinicaltrials.gov) - Mar 10, 2020
P1, N=36, Not yet recruiting, Sponsor: Atridia Pty Ltd.
- perfluorohexyloctane (NOV03) / Novaliq, Bausch Health
Effects of Perfluorohexyloctane on Signs and Symptoms of Dry Eye Disease: SEECASE-1: Subgroup Analysis based on Baseline Characteristics (Exhibit Hall: Posterboard# A0151) - Mar 9, 2020 - Abstract #ARVO2020ARVO_602;
P2
The same pattern was seen for CFB inDryness score for subjects with baseline MGD score ≥ 7 (point estimate of -13.39; p≤0.01) andSchirmer I test ≥ 10 (point estimate -19.96; p≤0.001)Conclusions Treatment with NOV03 QID significantly reduced corneal staining and severity of dryness in all subjects with DED compared to control. The improvements were greater in subjects with more pronounced evaporative DED characterized by higher MGD and Schirmer I test scores at baseline.
- | AiRuiKa (camrelizumab) / HLB Bio Group, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Enrollment open, Trial primary completion date: A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS) (clinicaltrials.gov) - Mar 9, 2020
P2, N=46, Recruiting, Sponsor: Fudan University
The improvements were greater in subjects with more pronounced evaporative DED characterized by higher MGD and Schirmer I test scores at baseline. Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2020 --> Jan 2021
- |||||||| AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New P3 trial, Monotherapy, BRCA Biomarker, PARP Biomarker: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy (clinicaltrials.gov) - Mar 9, 2020
P3, N=136, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma (clinicaltrials.gov) - Mar 9, 2020
P2, N=25, Recruiting, Sponsor: Fudan University
- ||| AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Enrollment open, Monotherapy: A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) - Mar 9, 2020
P1/2, N=66, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2020 --> Jan 2021 Not yet recruiting --> Recruiting
- AiTan (rivoceranib) / HLB Bio Group
Apatinib Inhibits Tumor Growth and Angiogenesis in PNET Models () - Mar 8, 2020 - Abstract #ENETS2020ENETS_3;
- imrecoxib (BAP 909) / Jiangsu Hengrui Medicine, celecoxib oral / Generic mfg.
[VIRTUAL] COST-EFFECTIVENESS ANALYSIS OF IMRECOXIB, CELECOXIB AND DICLOFENAC IN OSTEOARTHRITIS IN CHINA () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_1909;
In Chinese OA patients aged ≥65 years, the ICER was ＄3856 and ＄2738 for imrecoxib versus celecoxib and diclofenac, respectively, over a 6-month treatment duration. CONCLUSIONS With the gross domestic product/capita in Chinese in 2018 was ＄10407, the imrecoxib can be a cost-effective option over different treatment durations in Chinese OA patients.
- imrecoxib (BAP 909) / Jiangsu Hengrui Medicine, celecoxib oral / Generic mfg.
[VIRTUAL] EFFICACY AND SAFETY OF IMRECOXIB, CELECOXIB AND DICLOFENAC IN PATIENTS WITH OSTEOARTHRITIS- A NETWORK META-ANALYSIS () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_1902;
Since there were sparse RCTs have been reported for imrecoxib, the conclusion should be adopted with caution. Meanwhile, a nocebo effect was observed in the analysis of the rate of adverse events, which need further discussion.
- | AiTan (rivoceranib) / HLB Bio Group
Biomarker, Journal, Tumor microenvironment: High dose apatinib in the reversal of immunosuppressive tumor microenvironment for irradiation therapy in lung carcinoma. (Pubmed Central) - Mar 7, 2020
Meanwhile, a nocebo effect was observed in the analysis of the rate of adverse events, which need further discussion. No abstract available
- | AiTan (rivoceranib) / HLB Bio Group
Trial completion, Enrollment change, Trial completion date, Metastases: Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial (clinicaltrials.gov) - Mar 6, 2020
P2, N=30, Completed, Sponsor: Peking University People's Hospital
No abstract available Suspended --> Completed | N=100 --> 30 | Trial completion date: Jun 2021 --> Mar 2020
- | AiRuiKa (camrelizumab) / HLB Bio Group, Cosentyx (secukinumab) / Novartis
New P1/2 trial: A Trial of SHR-1210 in Combination With AIN457 in Patients With MSS CRC?SHR-1210-AIN457? (clinicaltrials.gov) - Mar 6, 2020
P1/2, N=40, Not yet recruiting, Sponsor: Yanqiao Zhang
- |||||||||| AiTan (rivoceranib) / HLB Bio Group
New P3 trial, BRCA Biomarker, PARP Biomarker: FABULOUS: A Study of Fluzoparib (clinicaltrials.gov) - Mar 5, 2020
P3, N=474, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 5, 2020
P2, N=20, Recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- || plinabulin (BPI 2358) / BeyondSpring
PK/PD data, Journal: Polymorphs, co-crystal structure and pharmacodynamics study of MBRI-001, a deuterium-substituted plinabulin derivative as a tubulin polymerization inhibitor. (Pubmed Central) - Mar 4, 2020
In vivo study, MBRI-001 revealed similar antitumor inhibition in comparison with plinabulin in A549 xenograft tumor model. Therefore, we suggested that MBRI-001 could be developed as a promising anti-cancer agent in near future.
- | AiTan (rivoceranib) / HLB Bio Group
Retrospective data, Journal: Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study. (Pubmed Central) - Mar 4, 2020
Therefore, we suggested that MBRI-001 could be developed as a promising anti-cancer agent in near future. Apatinib exhibits modest activity and acceptable toxicity for patients with heavily pretreated extensive-stage SCLC.
- |||| plinabulin (BPI 2358) / BeyondSpring
Enrollment open: Protective-1: Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 (clinicaltrials.gov) - Mar 4, 2020
P2/3, N=190, Recruiting, Sponsor: BeyondSpring Pharmaceuticals Inc.
Apatinib exhibits modest activity and acceptable toxicity for patients with heavily pretreated extensive-stage SCLC. Active, not recruiting --> Recruiting
- carboplatin / Generic mfg., AiTan (rivoceranib) / HLB Bio Group, Abraxane (albumin-bound paclitaxel) / Otsuka, BMS
Lower-dose apatinib combined with nanoparticle albumin-bound paclitaxel and carboplatin as a neoadjuvant regimen for triple negative breast cancer: a prospective, single-arm, phase 2 study (Exhibition area) - Mar 4, 2020 - Abstract #ESMOBC2020ESMO_BC_334;
- |||| AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma (clinicaltrials.gov) - Mar 4, 2020
P2, N=75, Recruiting, Sponsor: Sun Yat-sen University
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer (clinicaltrials.gov) - Mar 4, 2020
P2, N=80, Not yet recruiting, Sponsor: Huazhong University of Science and Technology
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery (clinicaltrials.gov) - Mar 4, 2020
P2, N=67, Recruiting, Sponsor: Shanghai Zhongshan Hospital
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Apatinib for hepatocellular carcinoma. (Pubmed Central) - Mar 3, 2020
Active, not recruiting --> Recruiting No abstract available
- | temozolomide / Generic mfg.
Trial completion date: Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma (clinicaltrials.gov) - Mar 3, 2020
P=N/A, N=60, Recruiting, Sponsor: Fuzhou General Hospital
No abstract available Trial completion date: Oct 2019 --> Oct 2020
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P2 trial: DAP-Her-01: Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer (clinicaltrials.gov) - Mar 3, 2020
P2, N=41, Not yet recruiting, Sponsor: Henan Cancer Hospital
- || AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
New P1 trial: Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment (clinicaltrials.gov) - Mar 3, 2020
P1, N=24, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- || AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
Clinical, Journal: Anti-PD-1 Antibody SHR-1210 combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study. (Pubmed Central) - Mar 2, 2020
SHR-1210 and apatinib combination therapy demonstrated manageable toxicity in HCC and GC/EGJC patients at recommended single-agent doses of both drugs. The RP2D for apatinib as combination therapy was 250 mg, which showed encouraging clinical activity in patients with advanced HCC.